Abstract
With eleven therapeutic antibodies approved worldwide and many more in clinical trials, research on antibody engineering has continued to escalate and expand. This review covers recent progress in generation of antibodies by ex vivo methods, systems for screening these, and the quest for higher affinity, more stable, optimally biodistributed antibody fragments, especially for solid tumors. The latest developments in engineering antibodies for removal or enhancement of effector functions (antibody-dependent cellular cytotoxicity (ADCC), phagosytosis, complement fixation (CDC) and halflife) through protein alteration or carbohydrate optimization may now enable generation of superior antibody therapeutics. Antibody conjugates, including immunotoxins and immunocytokines, as well as multivalent and multispecific antibodies confer expanded utility of therapeutic antibodies. Finally, research into the IgA / FcαRI system has now provided an additional route to therapeutic antibodies.
Keywords: antibodies, clinical trials, optimally biodistributed antibody, phagosytosis, carbohydrate optimization, therapeutic antibodies, anti-cancer mabs, fusion proteins
Current Pharmaceutical Biotechnology
Title: Engineering Antibodies for Therapy
Volume: 3 Issue: 3
Author(s): Leonard G. Presta
Affiliation:
Keywords: antibodies, clinical trials, optimally biodistributed antibody, phagosytosis, carbohydrate optimization, therapeutic antibodies, anti-cancer mabs, fusion proteins
Abstract: With eleven therapeutic antibodies approved worldwide and many more in clinical trials, research on antibody engineering has continued to escalate and expand. This review covers recent progress in generation of antibodies by ex vivo methods, systems for screening these, and the quest for higher affinity, more stable, optimally biodistributed antibody fragments, especially for solid tumors. The latest developments in engineering antibodies for removal or enhancement of effector functions (antibody-dependent cellular cytotoxicity (ADCC), phagosytosis, complement fixation (CDC) and halflife) through protein alteration or carbohydrate optimization may now enable generation of superior antibody therapeutics. Antibody conjugates, including immunotoxins and immunocytokines, as well as multivalent and multispecific antibodies confer expanded utility of therapeutic antibodies. Finally, research into the IgA / FcαRI system has now provided an additional route to therapeutic antibodies.
Export Options
About this article
Cite this article as:
Presta G. Leonard, Engineering Antibodies for Therapy, Current Pharmaceutical Biotechnology 2002; 3 (3) . https://dx.doi.org/10.2174/1389201023378256
DOI https://dx.doi.org/10.2174/1389201023378256 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
NK Cell Receptors and Their Interactions with MHC
Current Pharmaceutical Design Receptor Tyrosine Kinases Take a Direct Route to Mitochondria: An Overview
Current Protein & Peptide Science Fusogenic Oncolytic Herpes Simplex Viruses as a Potent and Personalized Cancer Vaccine
Current Pharmaceutical Biotechnology Large-Scale Prediction of Drug Targets Based on Local and Global Consistency of Chemical-Chemical Networks
Combinatorial Chemistry & High Throughput Screening Safety and Utilization of Blood Components as Therapeutic Delivery Systems
Current Pharmaceutical Biotechnology Perspectives for Novel Mixed Diruthenium-Organic Drugs as Metallopharmaceuticals in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Small Peptides as Modulators of Serine Proteases
Current Medicinal Chemistry Oncogenic Signalling Networks and Polypharmacology as Paradigms to Cope with Cancer Heterogeneity
Current Proteomics Monoclonal Antibody-based Genetic Immunotherapy
Current Gene Therapy Subject Index To Volume 1
Recent Patents on Anti-Cancer Drug Discovery The Diagnosis of Large Airway Pathology and the Role of Rigid Bronchoscopy
Current Respiratory Medicine Reviews Antibacterial and Antitumorigenic Properties of Microcin E492, a Pore- Forming Bacteriocin
Current Pharmaceutical Biotechnology Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews Nanocarriers for Tracking and Treating Diseases
Current Medicinal Chemistry MicroRNAs in Cancer Stem Cells: New Regulators of Stemness
Current Pharmaceutical Design Chemoradiotherapy of Human Tumors: Novel Approaches from Nanomedicine
Current Pharmaceutical Design Plant-Made Antibodies: Properties and Therapeutic Applications
Current Medicinal Chemistry Randomised Trials of Graft Versus Host Disease Prophylaxis in Haemopoietic Stem Cell Transplantation
Reviews on Recent Clinical Trials Targeting Transcription Factors for Cancer Gene Therapy
Current Gene Therapy Opportunities and Challenges for Niosomes as Drug Delivery Systems
Current Drug Delivery